Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium with the Concomitant Use of Proton Pump Inhibitors in Patients who Received Kidney Transplant

Objective: This study aims to describe and compare the transplant outcomes of kidney transplant (KTx) patients who received either mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium (EC-MPS) with the concomitant use of proton pump inhibitors (PPIs). 

Materials and Methods: This was a 9-year retrospective observational study conducted between 1 January 2011 and 31 December 2019 at ... Hospital, Nephrology Department, … University Faculty of Medicine.

Results: Among 349 KTx patients, 290 were eligible for the study with aged [median (interquartile range (IQR))] 41 (33-50) years in the MMF group and 41 (31-50) years in the EC-MPS group. More than half of them were male (54% in MMF vs. 60% in EC-MPS groups) and the majority received a living transplant (79% in both). There was no statistically significant difference in transplant outcomes including protein/creatinine ratio [(median (IQR)): 150 (2-308) vs. 153 (58-397), p=0.742], creatinine doubling (8% vs. 10%, p=0.589), change in medications (46% vs. 48%, p=0.775), delayed graft function (8% vs. 14%, p=0.153), biopsy-proven acute rejection (14% vs. 18%, p=0.327), graft loss (7% vs. 10%, p=0.351) and overall mortality (4% vs. 6%, p=0.337) among the patient groups who received either MMF or EC-MPS, respectively.

Conclusion: The transplant outcomes including graft survival, BPAR, graft loss, or delayed graft function of the KTx patients who received MMF or EC-MPS with PPIs were similar. Therefore, PPIs and MMF or EC-MPS can be prescribed together safely with appropriate follow-up intervals.

Cite this article as: Selçuk A, Pehlivanlı A, Eyüpoğlu Ş, Özçelikay AT, Şengül Ş. Mycophenolate mofetil and enteric-coated mycophenolate sodium with the concomitant use of proton pump inhibitors in patients who received kidney transplant. Turk J Nephrol. 2022;31(4):348-354.